TT-702 in Patients With Advanced Solid Tumours.

This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.

Trial Details

NCT ID

NCT05272709

Phase

PHASE1 / PHASE2

Sponsor

Cancer Research UK

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

TT-702
Darolutamide

Locations (sample)

London, United Kingdom|51.50853,-0.12574
Manchester, United Kingdom|53.48095,-2.23743
Southampton, United Kingdom|50.90395,-1.40428

Key Eligibility Criteria

Be able to provide informed consent and be capable of co-operating with IMP administration, procedures and follow-up.
Be willing to provide samples (blood and tissue) as required.
Consent to access any available archival tissue.
Consent for fresh tumour biopsy samples at baseline and on trial (may be Investigator mandated for patients in the dose escalation phase; mandatory…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →